Instylla, Inc.

Instylla is a privately held medical technology company based in Bedford, Massachusetts, founded in 2017. The company develops advanced resorbable embolic agents for interventional radiology, with primary clinical applications in interventional oncology and peripheral hemostasis. Instylla's flagship product, the Embrace™ Hydrogel Embolic System, is FDA-approved and represents the first and only liquid embolic approved specifically for hypervascular tumor embolization, supported by prospective randomized controlled clinical trials. The Embrace HES is a non-adhesive liquid embolic that penetrates to the capillary level, enabling targeted tumor treatment with favorable target lesion response and no recanalization. The system is designed for controlled and persistent embolization while being bioresorbable, leaving nothing behind and preserving future treatment options. The company also offers the Tembo™ Embolic System, consisting of resorbable gelatin particles for hypervascular tumor embolization and peripheral vascular occlusion. With approximately 34 employees and $7.4 million in reported revenue, Instylla has secured $63.8 million in total funding, positioning itself as an innovative leader in interventional oncology solutions.